Search

Four experiments evaluated the effect of implant dose and release pattern on performance and carcass traits of crossbred beef steers. In Exp. 1, steers (4 to 7 pens/treatment; initial BW = 315 kg) were fed an average of 174 ci. Treatments were 1) no implant (NI); 2) Revalor-S [120 mg of trenbolone acetate (TBA) and 24 mg of estradiol 17f3 (E2); REV-SI; 3) Revalor-IS followed by REV-S (cumulatively 200 mg of TBA and 40 mg of E2 reimplanted at 68 to 74 d; REVIS/S); and 4) Revalor-XS (200 mg of TBA and 40 mg of E2 REV-X), Carcass-adjusted final BW was greater (P < 0.05) for REV-X and REV-IS/S than for REV-S (610, 609, and 598 kg, respectively). Daily DM1 did not differ (P > 0.10) among the 3 implants, but carcassadjusted G:F was greater (P < 0.05) for REV-X and REV-IS/S than for REV-S (0.197 and 0.195 vs. 0.188). Both HCW and LM area were greater (P < 0.05) for REV-X and REV-IS/S than for REV-S. Marbling scores were greatest (P < 0.05) for REV-S and least (P < 0.05) for REV-IS/S; REV-X was intermediate to NI and REV-IS/S. In Exp. 2, steers (10 pens/treatment; initial BW = 391 kg) were fed 131 d, with treatments of REV-S, REV-IS/S (reimplanted at 44 to 47 d), and REV-X. Carcass-adjusted final BW (598 kg), ADG (1.6 kg), DM1 (9.4 kg), G:F (0.17), and HCW did not differ (P > 0.10) among treatments. The percentage of Choice was less (P < 0.05) and percentage of Select greater (P < 0.05) for REV-IS/S than for REV-S and REV-X. In Exp. 3, steers (10 pens/treatment; initial BW = 277 kg) were fed 197 d aud received either REVIS/S (reimplanted at 90 to 103 cI) or REV-X. Carcassadjusted final BW (625 vs. 633 kg) and ADG (1.81 vs. 1.76 kg) were greater (P < 0.05) for REV-X-implantecl steers. Daily DM1 did not differ, but G:F tended (P < 0.10) to be increased and HCW was greater (P < 0.05) for REV-X than for REV-IS/S. In Exp. 4, steers (8 pens/treatment; initial BW = 238 kg) were fed 243 d and received either REV-IS/S (reimplanted at 68 to 71 d) or REV-X. Carcass-adjusted final BW (612 kg), ADG (1.54 kg), DM1 (7.55), and G:F (0.21) did not differ (P > 0.10) for REV-IS/S and REV-X-implanted steers. Carcass traits did not differ among implants, but the percentage of Choice carcasses was greater (P < 0.05) and percentage of Select was less (P < 0.05) for REV-X than for REV-IS/S. These data indicate that when TBA/E2 dose is equal, the altered release rate of REV-X can improve performance and quality grade, but these effects depend on duration of the feeding period and timing of initial and terminal implants. [ABSTRACT FROM AUTHOR]

This experiment evaluated the dose and payout pattern of trenbolone acetate (TBA) and estradiol-17β (E2) on LM mRNA expression of adenosine monophosphate-activated protein kinase-ɑ (AMPK-ɑ), C/EBPβ, G protein-coupled receptor 41(GPR41), G protein-coupled receptor 43 (GPR43), PPARγ, and stearoyl CoA desaturase (SCD) in finishing feedlot steers as indicators of adipogenesis and marbling development. British · Continental steers (n = 168; 14 pens/treatment; initial BW = 362 kg) were used in a randomized complete block design. Treatments included: no implant (NI), Revalor-S (REV-S; 120 mg TBA + 24 mg E2), or Revalor-XS (REV-X; delayed release implant: 80 mg TBA + 16 mg E2 [uncoated], 120 mg TBA + 24 mg E2 [coated], 200 mg TBA + 40 mg E2 [total]). Steers were fed 1 time daily for an average of 164 d. The LM biopsies were collected (1 steer/pen) on d -1, 27, 55, and 111 relative to timing of implant. Total RNA was isolated from each sample and real-time quantitative PCR was used to measure quantity of AMPK-ɑ, C/EBPβ, GPR41, ,it, PPARγ, and SCD mRNA. No implant · day interactions were detected (P ≥ 0.19) in this experiment. Day impacted the mRNA expression of all adipogenic genes (P ≤ 0.02). The main effect of implant tended (P = 0.09) to influence expression of AMPK-ɑ, REV-X had an 8.8% increase over NI and an 18.7% increase over REV-S. Implant influenced (P = 0.03) mRNA expression of GPR41, expression of GPR41 for the REV-X treatment was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.13, 1.00, and 0.67 ± 0.224 arbitrary units) for REV-X, NI, and REV-S, respectively. Implant also influenced (P = 0.02) expression of GPR43, expression of GPR43 for REV-X was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.27, 1.07, and 0.72 ± 0.234 arbitrary units) for REV-X, NI, and REV-S, respectively. Implant influenced (P = 0.02) mRNA expression of PPARγ in LM tissue, expression of PPARγ for REV-X was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.09, 1.02, and 0.69 ± 0.195 arbitrary units) for REV-X, NI, and REV-S, respectively. The REV-X steers received the greatest anabolic dose of TBA + E2 without detriment to marbling scores. The increased mRNA expression of adipogenic genes for REV-X steers suggest that the delayed and gradual release of anabolic stimulants associated with REV-X might have mitigated decreases in marbling generally attributed to multiple combined TBA + E2 implants. [ABSTRACT FROM AUTHOR]